The Australian respiratory market seems set for a potential spurt in activity. Cipla and Sandoz appear to be gearing to take their respective competing versions of GlaxoSmithKline’s Seretide to Australia, piling up pressure on the UK multinational’s therapy there.
Cipla Ltd. and Sandoz Pty Ltd appear to have received registrations for their respective fluticasone propionate/salmeterol therapies in Australia – the Indian firm for its metered dose inhaler, while Sandoz for its AirFluSal Forspiro 500/50 fluticasone propionate/salmeterol xinafoate actuation powder for inhalation.
Cipla has received registration for fluticasone propionate and salmeterol in two strengths – 125/25 µg and 250/25 µg, particulars culled...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
